Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics

CNCE POWR Grades

• Sentiment is the dimension where CNCE ranks best; there it ranks ahead of 98.62% of US stocks.
• CNCE's strongest trending metric is Momentum; it's been moving down over the last 49 weeks.
• CNCE's current lowest rank is in the Momentum metric (where it is better than 7.05% of US stocks).

CNCE Stock Summary

• Of note is the ratio of Concert Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 10.39% of US stocks have a lower such ratio.
• Revenue growth over the past 12 months for Concert Pharmaceuticals Inc comes in at 422.52%, a number that bests 98.09% of the US stocks we're tracking.
• In terms of volatility of its share price, CNCE is more volatile than 96.34% of stocks we're observing.
• If you're looking for stocks that are quantitatively similar to Concert Pharmaceuticals Inc, a group of peers worth examining would be CARA, RCUS, KLDO, ANAB, and DTIL.
• CNCE's SEC filings can be seen here. And to visit Concert Pharmaceuticals Inc's official web site, go to www.concertpharma.com.

CNCE Valuation Summary

• In comparison to the median Healthcare stock, CNCE's EV/EBIT ratio is 100.68% lower, now standing at -0.2.
• Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.
• Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.

Below are key valuation metrics over time for CNCE.

CNCE Growth Metrics

• Its 3 year cash and equivalents growth rate is now at 60.69%.
• Its year over year net cashflow from operations growth rate is now at -10.21%.
• The 5 year revenue growth rate now stands at -99.88%.

CNCE's revenue has moved down $33,199,000 over the prior 67 months.

The table below shows CNCE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	33.53	-46.553	-58.542
2021-03-31	7.9	-71.917	-76.958
2020-12-31	7.902	-69.037	-74.766
2020-09-30	7.908	-67.885	-72.863
2020-06-30	6.417	-63.26	-71.14
2020-03-31	0.079	-65.257	-76.817

CNCE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CNCE has a Quality Grade of B, ranking ahead of 78.61% of graded US stocks.
• CNCE's asset turnover comes in at 0.223 -- ranking 188th of 680 Pharmaceutical Products stocks.
• SRNE, VBLT, and ISEE are the stocks whose asset turnover ratios are most correlated with CNCE.

The table below shows CNCE's key quality metrics over time.